NCT03190616已完成2 期
A Single Arm, Open Label, Multicenter Exploratory Study of Apatinib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Second Line Therapy
The First Affiliated Hospital with Nanjing Medical University4 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2017年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 4
- 主要终点
- Progression-free Survival(PFS)
研究概览
简要总结
Limited agents have been approved after standard first and second line treatment. Regorafenib and Trifluridine/Tipiracil (TAS-102) are still not approved in China.Apatinib has shown significant efficacy in refractory advanced gastric cancer regarding PFS and OS with controllable toxicity.This study is aimed to explore the efficacy,safety as well as predictive biomarker in advanced colorectal cancer failed to standard therapy in Chinese population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.
- •Subjects with metastatic colorectal cancer(CRC) (Stage IV).
- •Subjects must have failed at least two lines of prior treatment, which must include a fluoropyrimidine, oxaliplatin and irinotecan.
- •Subjects treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy.
- •Subjects who have withdrawn from standard treatment due to unacceptable toxicity and precluding retreatment with the same agent prior to progression of disease will also be allowed.
- •Prior treatment with bevacizumab and/or cetuximab will be allowed.
- •Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1.is necessary.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-
- •Life expectancy of at least 3 months.
- •Adequate bone marrow, liver and renal function as assessed by the laboratory required by protocol.
- •assigned informed consent.
排除标准
- •Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
- •Participants of other clinical trial within 4 weeks.
- •Diseases which will impact the absorption of apatinib, eg. dysphagia, chronic diarrhea, bowl obstruction
- •Hemorrhage events of ≥grade 3 within 4 weeks.
- •known central nervous system metastasis.
- •Uncontrolled hypertension. (Systolic blood pressure 140 mmHg or diastolic pressure 90 mmHg despite optimal medical management). Unstable angina,congestive heart failure,Myocardial infarction, Cardiac arrhythmias requiring anti-arrhythmic therapy.
- •urine protein ≥++ and 24h urine protein more than 1.0g.
- •Chronically green wound or bone fracture.
- •Arterial or venous thrombotic or embolic events.
- •Tumor invading important blood vessel with high risk of severe hemorrhage.
- •Abnormal coagulation function.
- •thromboemboli events within 6 months.
研究组 & 干预措施
drug,apatinib
Experimental
apatinib 500mg/qd, 28d/cycle
干预措施: apatinib (Drug)
结局指标
主要结局
Progression-free Survival(PFS)
时间窗: From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before Mar 30,2019
PFS was defined as the time from assignment to disease progression radiological/clinical or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation.
次要结局
- Overall Survival (OS)(From assignment of the first subject until 40 death events observed, up to 2 years.)
- Disease control rate (DCR)(From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before Mar 30,2019)
- Objective response rate(ORR)(From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before Mar 30,2019)
- Quality of life(From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before Mar 30,2019)
- relationship between the tumor molecular burden & gene mutation and the drug efficacy.(From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before Mar 30,2019.)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(From assignment of the first subject to 3 months later after the last participant is recruited.The last participant will be recruited before Mar 30,2019.)
研究者
Gu Yanhong
Professor
The First Affiliated Hospital with Nanjing Medical University
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Redirected MazF-CD4 Autologous T Cells for HIV Gene TherapyHIVNCT01787994University of Pennsylvania10
已完成
2 期
Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active HemolysisNCT03439839Novartis Pharmaceuticals16
招募中
2 期
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell NeoplasmsB-Cell NeoplasmNCT06508931Miltenyi Biomedicine GmbH31
已完成
2 期
Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIentsMetastatic Thymic CarcinomaThymoma Type B3NCT04710628MedSIR43
已完成
2 期
First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal CancerColorectal Cancer MetastaticNCT01163396Gruppo Oncologico del Nord-Ovest57